Study: Eli Lilly and Company N1T-MC-MALO “SYNERGY-OUTCOMES”
This is a Phase 3 study evaluating how retatrutide and tirzepatide (Zepbound) may slow the progression of high-risk metabolic fatty liver disease (MASLD) and help prevent serious liver complications.
This is a placeholder and I’ll delete it.
This is a placeholder post for the moment. We can remove this anytime.